Mechanisms of resistance to EGFR inhibitors

Targeted Oncology

Volumn 2, Issue 1, 2007, Pages 31-37

  Bianco, Roberto ^a   Gelardi, Teresa ^a   Damiano, Vincenzo ^a   Ciardiello, Fortunato ^b   Tortora, Giampaolo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Drug resistance; Epidermal growth factor receptor (EGFR); Targeted therapies

Indexed keywords

EID: 33846134006     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-006-0038-x     Document Type: Review

References (62)

1. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5:341-354
2. Citri A, Yarden Y (2006) EGF-ERBB signaling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516
3. Alaoui-Jamali MA, Qiang H (2003) The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery. Drug Resist Updat 6:95-107
4. Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 19:183-232
5. Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832
6. Mendelsohn J, Baselga J (2006) Epidermal growth factor receptor targeting in cancer. Semin Oncol 33:369-385
7. Saif MW, Cohenuram M (2006) Role of panitumumab in the management of metastatic colorectal cancer. Clin Colorectal Cancer 6:118-124
8. Mateo C, Moreno E, Amour K et al (1997) Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor. Recovery of antagonistic activity. Immunotechnology 3:71-81
9. Bode U, Buchen S, Janssen G et al (2006) Results of a phase II trial of h-R3 monoclonal activity (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. Proc Am Soc Clin Oncol A1522
10. Ferrara N, Kerbel R (2005) Angiogenesis as therapeutic target. Nat Med 438:967-974
11. Goldman CK, Kim J, Wong WL et al (1993) Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 4:121-133
12. Gille J, Swerlick RA, Caughman SW (1997) Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J 17:750-759
13. Ciardiello F, Caputo R, Troiani T, et al (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 15:172-178
14. O-charoenrat P, Rhys-Evans P, Modjtahedi H et al (2000) Vascular endothelial growth factor family members are differentially regulated by c-erbB signaling in head and neck squamous carcinoma cells. Clin Exp Metastasis 18:155-161
15. Ravindranath N, Wion D, Brachet P et al (2001) Epidermal growth factor modulates the expression of vascular endothelial growth factor in the human prostate. J Androl 22:432-443
16. Ciardiello F, Damiano V, Bianco R et al (1996) Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J Natl Cancer Inst 4:1770-1776
17. Petit AM, Rak J, Hung MC et al (1997) Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530
18. Perrotte P, Matsumoto T, Inoue K et al (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5:257-265
19. Ciardiello F, Bianco R, Damiano V et al (2000) Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6:3739-3747
20. Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090-5101
21. Viloria-Petit AM, Kerbel RS (2004) Acquired resistance to EGFR inhibitors mechanisms and prevention strategies. Int J Radiat Oncol Biol Phys 1:914-926
22. Ciardiello F, Bianco R, Caputo R et al (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 15:784-793
23. Vallbohmer D, Zhang W, Gordon M et al (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536-3544
24. Takahashi Y, Bucana CD, Liu W et al (1996) Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J Natl Cancer Inst 88:1146-1151
25. Samani AA, Yakar S, Leroith D et al (2006) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev DOI 10.1210/er.2006-0001
26. Nickerson T, Chang F, Lorimer D et al (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor 1 (IGF-1) and IGF-1 receptor (IGF-1R). Cancer Res 61:6276-6280
27. Chakravarti A, Loeffler JS, Dyson NJ (2002) Insulin-like growth factor receptor I mediates resistance to antiepidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 1:200-207
28. Jones HE, Goddard L, Gee JM et al (2004) Insulin-like growth factor-I receptor signaling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11:793-814
29. Lu Y, Zi X, Zhao Y et al (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93:1852-1857
30. Morgillo F, Woo JK, Kim ES et al (2006) Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 66:10100-10111
31. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2:489-501
32. Janmaat ML, Kruyt FA, Rodriguez JA et al (2003) Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 9:2316-2326
33. Kolch W, Calder M, Gilbert D (2005) When kinases meet mathematics: the systems biology of MAPK signaling. FEBS Lett 579:1891-1895
34. Perez-Soler R, Ling Y, Lia M (2003) Molecular mechanisms of resistance to the HER/EGFR tyrosine kinase inhibitor erlotinib HCL in human cancer cell lines. Proceedings of Annual Meeting of the American Society of Clinical Oncology, Chicago, p 190
35. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6:184-192
36. Li DM, Sun H (1998) PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. PNAS 22:15406-15411
37. Lu D, Zhang H, Ludwig D et al (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279:2856-2865
38. Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 8:2812-2822
39. She QB, Solit D, Basso A et al (2003) Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3k-kinase/Akt pathway signaling. Clin Cancer Res 1:4340-4346
40. Nagata Y, Lan KH, Zhou X et al (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117-127
41. Rojo F, Tabernero J, Albanell J et al (2006) Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J Clin Oncol 26:4309-4316
42. Dehm SM, Bonham K (2004) SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol 82:263-274
43. Aligayer H, Boyd DD, Heiss MM (2002) Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer 94:344-345
44. Wiener JR, Windham TC, Estrella VC (2003) Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol 88:73-79
45. Qin B, Ariyama H, Baba E et al (2006) Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells. Cancer Chemother Pharmacol 58:577-584
46. Normanno N, De Luca A, Maiello MR et al (2006) The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207:420-427
47. Ni Z, Lou W, Leman ES et al (2000) Inhibition of constitutively activated STAT-3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res 60:1225-1228
48. Garcia R, Bowman TL, Niu G et al (2001) Constitutive activation of STAT-3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513
49. Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL et al (2002) STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo. Cell Growth Differ 13:355-362
50. Garcia de Palazzo IE, Adams GP, Sundareshan P et al (1993) Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res 53:3217-3220
51. Lorimer IA (2002) Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2:91-102
52. Li B, Yuan M, Kim IA et al (2004) Mutant epidermal growth factor receptor displays increased signalling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene 23:4594-4602
53. Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83-96
54. Learn CA, Hartzell TL, Wikstrand CJ et al (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 1:3216-3224
55. Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 4:1497-1500
56. Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 20:2129-2139
57. Sordella R, Bell DW, Haber DA et al (2004) Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 20:1163-1167
58. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. PNAS 7:13306-13311
59. Kobayashi S, Ji H, Yuza Y et al (2005) EGFR mutation and resistance of non-small cell lung cancer to gefitinib. N Engl J Med 352:786-792
60. Pao W, Miller VA, Politi KA et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73
61. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 29:46265-46272
62. Blencke S, Ullrich A, Daub H (2003) Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J Biol Chem 278:15435-15440